Ignite Creation Date:
2024-05-06 @ 12:30 PM
Last Modification Date:
2024-10-26 @ 12:59 PM
Study NCT ID:
NCT03774784
Status:
TERMINATED
Last Update Posted:
2020-06-16
First Post:
2018-12-11
Brief Title:
A Study of the Natural History of Leukocyte Chemotactic Factor 2 Amyloidosis ALECT2 Disease
Sponsor:
Alnylam Pharmaceuticals
Organization:
Alnylam Pharmaceuticals
Study Overview
Official Title:
A Study of the Natural History of Leukocyte Chemotactic Factor 2 Amyloidosis ALECT2 Disease
Status:
TERMINATED
Status Verified Date:
2020-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
The study was terminated due to the impacts of COVID-19 on patient safety and enrollment
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to characterize the natural history of leukocyte chemotactic factor 2 amyloidotic ALECT2 disease In this observational study participants with ALECT2 disease will be enrolled Participants who have already reached end-stage renal disease ESRD will provide retrospective chart review data and biological specimens at baseline only Other participants in addition to retrospective chart review will be followed prospectively
Detailed Description:
Refer to wwwstudyALECT2com
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None